Canada is facing a mental health and addiction crisis that costs nearly $180 billion annually, while many existing treatments fail patients—including veterans, first responders, and those in palliative care—leaving them with limited effective options. Physician-prescribed psilocybin-assisted therapy shows promise as a supervised treatment for PTSD, addiction, and end-of-life care, but access remains hindered by the burdensome Special Access Program (SAP), which forces doctors and patients to navigate unnecessary red tape.

In more than 200 cases, courts have had to intervene to compel Health Canada to grant access to recommended psilocybin treatment—highlighting systemic barriers and a clear need for reform. Notably, the previous Conservative government had proposed ending the SAP altogether, recognizing it as outdated, bureaucratic, and unfair to patients.

Psilocybin (Magic Mushrooms) -assisted therapy, when combined with counseling and administered under the supervision of qualified healthcare professionals, offers new hope for individuals seeking effective treatment options:

• Helping veterans and trauma survivors find lasting relief from PTSD and depression.
• Supporting addiction recovery with safe, non-addictive, and effective treatment options.
• Offering palliative care patients relief and dignity as a compassionate alternative to Medical Assistance in Dying (MAID).

The current Special Access Program (SAP) forces doctors and patients to fight through unnecessary red tape.

The Opportunity:

Psilocybin, when used alongside counselling, has shown strong clinical results in treating conditions such as PTSD, depression, and addiction. It is non-toxic and non-addictive, offering a natural alternative to SSRI's, and does not produce physical dependence or withdrawal symptoms like opioids, nicotine, or alcohol.

In the context of compassionate end-of-life care, psilocybin-assisted therapy provides an evidence-based option that can reduce depression, anxiety, and fear of death in terminally ill patients, helping foster a sense of peace, acceptance, and dignity. At the same time, U.S. Phase 3 trials are nearing completion, with the FDA signaling support for potential medical approval.

Thomas’ bill proposes that medicines that contain psilocybin and/or psilocin go through Health Canada’s priority review process, thereby sending these medicines through a streamlined review process. Approximately 4500 Canadians take their own lives every year, psilocybin has the potential to bring this number down substantially, therefore it is crucial that these medicines go through Health Canada’s review process as quickly as possible.